Haemolysis risk in methylene blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs (2012)

Peer-Reviewed Study · Müller O; Mockenhaupt FP; Marks B; Meissner P; Coulibaly B; Kuhnert R; Buchner H; Schirmer RH; Walter-Sack I; Sié A; Mansmann U · November 7, 2012

Müller O et al., 2012-11-07: Pooled individual-patient analysis of four West African trials (1005 children) finding methylene blue at 15 mg/kg/day significantly lowers haemoglobin in children with full G6PD deficiency, with two haemolysis episodes among 1005 children; the authors judge the effect of limited clinical relevance but requiring monitoring.

In children with hemi- or homozygous G6PD (A-) deficiency, MB treatment with 15 mg/kg per day was associated with a significant reduction in Hb values which reached a minimum of 8.5 g/dl.

Abstract

Müller O et al., 2012-11-07: Pooled individual-patient analysis of four West African trials (1005 children) finding methylene blue at 15 mg/kg/day significantly lowers haemoglobin in children with full G6PD deficiency, with two haemolysis episodes among 1005 children; the authors judge the effect of limited clinical relevance but requiring monitoring. Study type: pooled analysis of four randomised controlled trials (2003-2007). N=1005 children; 199 G6PD-deficient, 806 sufficient; 844 received MB-containing regimens, 161 did not. MB 15 mg/kg/day oral was the dose associated with the Hb effect. Comparator: MB-free regimens within the same trials. Funder/COI not stated in retrieved abstract record. This is the clearest safety caveat in the Burkina programme: mild but real haemolysis risk in fully G6PD-deficient children. Also filed as MTO-25, MTO-65, MTI-114 (claims C1, C10, C3).